Advertisement

MMW - Fortschritte der Medizin

, Volume 160, Supplement 2, pp 32–35 | Cite as

HIV-Reservoir in ruhenden CD4-T-Zellen

Barriere auf dem Weg zur Heilung

  • Maximilian MuenchhoffEmail author
  • Oliver T. Keppler
FORTBILDUNG . ÜBERSICHT
  • 90 Downloads

Die größte Hürde zu einer Heilung der HIV-Infektion ist bis heute das virale Reservoir, in dem replikationsfähige Viren selbst unter der antiretroviralen Therapie persistieren. Wie ist hier der Stand der Forschung?

The HIV reservoir in resting CD4 T-cells: Barrier on the road to an HIV cure

Keywords

HIV persistence HIV reservoir HIV cure antiretroviral therapy 

Literatur

  1. 1.
    Davey RT, Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proceedings of the National Academy of Sciences of the United States of America (1999) 96(26):15109–14. PubMed PMID: 10611346; PubMed Central PMCID: PMC24781.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature medicine (2016) 22(8):839–50. doi: 10.1038/nm.4108. PubMed PMID: 27400264; PubMed Central PMCID: PMC5322797.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Venzke S, Keppler OT. Role of macrophages in HIV infection and persistence. Expert review of clinical immunology (2006) 2(4):613–26. doi: 10.1586/1744666X.2.4.613. PubMed PMID: 20477617.CrossRefPubMedGoogle Scholar
  4. 4.
    Battistini A, Sgarbanti M. HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 6(4):1715–58. doi: 10.3390/v6041715. PubMed PMID: 24736215; PubMed Central PMCID: PMC4014718.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature medicine (2009) 15(8):893–900. doi: 10.1038/nm.1972. PubMed PMID: 19543283; PubMed Central PMCID: PMC2859814.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gray LR, Roche M, Flynn JK, Wesselingh SL, Gorry PR, Churchill MJ. Is the central nervous system a reservoir of HIV-1? Current opinion in HIV and AIDS (2014) 9(6):552–8. doi: 10.1097/COH.0000000000000108. PubMed PMID: 25203642; PubMed Central PMCID: PMC4215931.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nature medicine (2017) 23(11):1271–6. doi: 10.1038/nm.4411. PubMed PMID: 28967921; PubMed Central PMCID: PMC5831193.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, et al. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. Journal of clinical microbiology (2014) 52(11):3944–51. doi: 10.1128/JCM.02060-14. PubMed PMID: 25187636; PubMed Central PMCID: PMC4313209.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    van Zyl G, Bale MJ, Kearney MF. HIV evolution and diversity in ART-treated patients. Retrovirology (2018) 15(1):14. doi: 10.1186/s12977-018-0395-4. PubMed PMID: 29378595; PubMed Central PMCID: PMC5789667.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature (2016) 530(7588):51–6. doi: 10.1038/nature16933. PubMed PMID: 26814962; PubMed Central PMCID: PMC4865637.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
  12. 12.
    Frange P, Faye A, Avettand-Fenoel V, Bellaton E, Descamps D, Angin M, et al. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. The lancet HIV (2016) 3(1):e49–54. doi: 10.1016/S2352-3018(15)00232-5. PubMed PMID: 26762993.CrossRefPubMedGoogle Scholar
  13. 13.
    Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS pathogens (2013) 9(3):e1003211. doi: 10.1371/journal.ppat.1003211. PubMed PMID: 23516360; PubMed Central PMCID: PMC3597518.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ananworanich J, Chomont N, Eller LA, Kroon E, Tovanabutra S, Bose M, et al. HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART. EBioMedicine (2016) 11:68–72. doi: 10.1016/j.ebiom.2016.07.024. PubMed PMID: 27460436; PubMed Central PMCID: PMC5049918.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Early HIV Infection May Hold the Key to a Potential Cure [3.3.2018]. Available from: http://amfar.org/Key-to-Potential-Cure/.
  16. 16.
    Wang CX, Cannon PM. The clinical applications of genome editing in HIV. Blood (2016) 127(21):2546–52. doi: 10.1182/blood-2016-01-678144. PubMed PMID: 27053530; PubMed Central PMCID: PMC4882804.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Porichis F, Kaufmann DE. Role of PD-1 in HIV pathogenesis and as target for therapy. Current HIV/AIDS reports (2012) 9(1):81–90. doi: 10.1007/s11904-011-0106-4. PubMed PMID: 22198819; PubMed Central PMCID: PMC3731769.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife (2014) 3:e03821. doi: 10.7554/eLife.03821. PubMed PMID: 25217531; PubMed Central PMCID: PMC4199415.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Descours B, Petitjean G, Lopez-Zaragoza JL, Bruel T, Raffel R, Psomas C, et al. CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses. Nature (2017) 543(7646):564–7. doi: 10.1038/nature21710. PubMed PMID: 28297712.CrossRefPubMedGoogle Scholar
  20. 20.
    Raposo RA, de Mulder Rougvie M, Paquin-Proulx D, Brailey PM, Cabido VD, Zdinak PM, et al. IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI insight (2017) 2(1):e85811. doi: 10.1172/jci.insight.85811. PubMed PMID: 28097226; PubMed Central PMCID: PMC5214598.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Siliciano RF, Greene WC. HIV latency. Cold Spring Harbor perspectives in medicine (2011) 1(1):a007096. doi: 10.1101/cshperspect.a007096. PubMed PMID: 22229121; PubMed Central PMCID: PMC3234450.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Virologie, Nationales Referenzzentrum für Retroviren Max von Pettenkofer-Institut, Ludwig-Maximilians-Universität München (LMU)MünchenDeutschland
  2. 2.German Center for Infection Research (DZIF)MünchenDeutschland

Personalised recommendations